JOP20230102A1 - مثبط إنتجرين واستخداماته - Google Patents
مثبط إنتجرين واستخداماتهInfo
- Publication number
- JOP20230102A1 JOP20230102A1 JOJO/P/2023/0102A JOP20230102A JOP20230102A1 JO P20230102 A1 JOP20230102 A1 JO P20230102A1 JO P20230102 A JOP20230102 A JO P20230102A JO P20230102 A1 JOP20230102 A1 JO P20230102A1
- Authority
- JO
- Jordan
- Prior art keywords
- methods
- integrin inhibitor
- crystalline forms
- integrin inhibitors
- forms
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
- C07C309/01—Sulfonic acids
- C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
- C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
- C07C309/35—Naphthalene sulfonic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063116042P | 2020-11-19 | 2020-11-19 | |
| PCT/US2021/072510 WO2022109598A1 (en) | 2020-11-19 | 2021-11-19 | Integrin inhibitor and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JOP20230102A1 true JOP20230102A1 (ar) | 2023-05-08 |
Family
ID=81709878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOJO/P/2023/0102A JOP20230102A1 (ar) | 2020-11-19 | 2023-05-08 | مثبط إنتجرين واستخداماته |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US12018025B2 (enExample) |
| EP (1) | EP4247472A4 (enExample) |
| JP (1) | JP2023550428A (enExample) |
| KR (1) | KR20230121761A (enExample) |
| CN (1) | CN116710169A (enExample) |
| AU (1) | AU2021381516A1 (enExample) |
| CA (1) | CA3173755A1 (enExample) |
| CL (1) | CL2023001418A1 (enExample) |
| CO (1) | CO2023006522A2 (enExample) |
| CR (1) | CR20230262A (enExample) |
| CU (1) | CU20230026A7 (enExample) |
| DO (1) | DOP2023000101A (enExample) |
| EC (1) | ECSP23045278A (enExample) |
| IL (1) | IL302651A (enExample) |
| JO (1) | JOP20230102A1 (enExample) |
| MX (1) | MX2023005889A (enExample) |
| PE (1) | PE20240114A1 (enExample) |
| TW (1) | TW202235417A (enExample) |
| WO (1) | WO2022109598A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE50554E1 (en) | 2016-12-23 | 2025-08-26 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| US11419869B2 (en) | 2019-04-08 | 2022-08-23 | Pliant Therapeutics, Inc. | Dosage forms and regimens for amino acid compounds |
| CN120091811A (zh) * | 2022-07-09 | 2025-06-03 | 普利安特治疗公司 | 整合素抑制剂及其与其它药剂组合的用途 |
| WO2024155965A2 (en) * | 2023-01-21 | 2024-07-25 | Pliant Therapeutics, Inc. | Biomarkers for use in integrin inhibitor therapy |
| WO2025072206A1 (en) * | 2023-09-25 | 2025-04-03 | Pliant Therapeutics, Inc. | Integrin inhibitors for treatment of primary sclerosing cholangitis |
| TW202535400A (zh) | 2023-12-14 | 2025-09-16 | 美商普萊恩醫療公司 | 整合素抑制劑及其用途 |
| WO2025217571A1 (en) * | 2024-04-12 | 2025-10-16 | Pliant Therapeutics, Inc. | Fixed dose combinations of integrin inhibitor with ppar agonists |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013184572A1 (en) * | 2012-06-04 | 2013-12-12 | Pharmacyclics, Inc. | Crystalline forms of a bruton's tyrosine kinase inhibitor |
| WO2015048819A1 (en) | 2013-09-30 | 2015-04-02 | The Regents Of The University Of California | Anti-alphavbeta1 integrin compounds and methods |
| CA2981371A1 (en) | 2015-03-10 | 2016-09-15 | The Regents Of The University Of California | Anti-alphavbeta1 integrin inhibitors and methods of use |
| CN109996541A (zh) | 2016-09-07 | 2019-07-09 | 普利安特治疗公司 | N-酰基氨基酸化合物及其使用方法 |
| USRE50554E1 (en) | 2016-12-23 | 2025-08-26 | Pliant Therapeutics, Inc. | Amino acid compounds and methods of use |
| SG11201907820SA (en) | 2017-02-28 | 2019-09-27 | Morphic Therapeutic Inc | Inhibitors of (alpha-v)(beta-6) integrin |
| US11046685B2 (en) | 2017-02-28 | 2021-06-29 | Morphic Therapeutic, Inc. | Inhibitors of (α-v)(β-6) integrin |
| LT3761980T (lt) | 2018-03-07 | 2024-03-12 | Pliant Therapeutics, Inc. | Aminorūgščių junginiai ir jų panaudojimo būdai |
| TWI841573B (zh) | 2018-06-27 | 2024-05-11 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
| WO2020016704A1 (ja) * | 2018-07-20 | 2020-01-23 | 株式会社半導体エネルギー研究所 | 撮像パネル、撮像装置 |
| CA3109534A1 (en) | 2018-08-29 | 2020-03-05 | Morphic Therapeutic, Inc. | Inhibiting .alpha.v .beta.6 integrin |
| EP3843727A4 (en) | 2018-08-29 | 2022-08-17 | Morphic Therapeutic, Inc. | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN |
| ES3027421T3 (en) | 2018-08-29 | 2025-06-13 | Morphic Therapeutic Inc | Inhibitors of (alpha-v)(beta-6) integrin |
| TW202028179A (zh) | 2018-10-08 | 2020-08-01 | 美商普萊恩醫療公司 | 胺基酸化合物及使用方法 |
| EP3903316A1 (en) * | 2018-12-28 | 2021-11-03 | LunaPBC | Community data aggregation, completion, correction, and use |
| EP3923857B8 (en) * | 2019-02-15 | 2024-04-17 | Clean Bite, LLC | Oral hygiene appliance |
| US11419869B2 (en) * | 2019-04-08 | 2022-08-23 | Pliant Therapeutics, Inc. | Dosage forms and regimens for amino acid compounds |
| EP4058481A1 (en) | 2019-11-15 | 2022-09-21 | Pliant Therapeutics, Inc. | Compositions and methods for activation of integrins |
| CN115989235A (zh) | 2020-05-07 | 2023-04-18 | 普利安特治疗公司 | 使用氨基酸化合物治疗呼吸系统疾病的方法 |
| TWI838626B (zh) * | 2020-06-03 | 2024-04-11 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| WO2022087224A1 (en) * | 2020-10-21 | 2022-04-28 | Cohbar, Inc. | Method of treating fibrosis with a combination therapy |
| CA3173787A1 (en) | 2021-04-30 | 2022-11-03 | Scott Turner | Expanded dosage regimens for integrin inhibitors |
| US20240350494A1 (en) | 2021-09-03 | 2024-10-24 | Pliant Therapeutics, Inc. | Therapeutic modulation of integrins |
| EP4416147A1 (en) | 2021-10-14 | 2024-08-21 | Pliant Therapeutics, Inc. | Integrin inhibitors and uses thereof in combination with other agents |
| WO2023225119A1 (en) | 2022-05-18 | 2023-11-23 | Pliant Therapeutics, Inc. | Stabilization of integrin inhibitors |
-
2021
- 2021-11-19 CR CR20230262A patent/CR20230262A/es unknown
- 2021-11-19 AU AU2021381516A patent/AU2021381516A1/en not_active Abandoned
- 2021-11-19 TW TW110143265A patent/TW202235417A/zh unknown
- 2021-11-19 US US17/531,074 patent/US12018025B2/en active Active
- 2021-11-19 JP JP2023530225A patent/JP2023550428A/ja active Pending
- 2021-11-19 WO PCT/US2021/072510 patent/WO2022109598A1/en not_active Ceased
- 2021-11-19 CN CN202180090550.5A patent/CN116710169A/zh active Pending
- 2021-11-19 MX MX2023005889A patent/MX2023005889A/es unknown
- 2021-11-19 CA CA3173755A patent/CA3173755A1/en active Pending
- 2021-11-19 EP EP21895890.8A patent/EP4247472A4/en not_active Withdrawn
- 2021-11-19 PE PE2023001662A patent/PE20240114A1/es unknown
- 2021-11-19 KR KR1020237020570A patent/KR20230121761A/ko not_active Withdrawn
- 2021-11-19 IL IL302651A patent/IL302651A/en unknown
- 2021-11-19 CU CU2023000026A patent/CU20230026A7/es unknown
-
2023
- 2023-05-08 JO JOJO/P/2023/0102A patent/JOP20230102A1/ar unknown
- 2023-05-17 CL CL2023001418A patent/CL2023001418A1/es unknown
- 2023-05-17 CO CONC2023/0006522A patent/CO2023006522A2/es unknown
- 2023-05-18 DO DO2023000101A patent/DOP2023000101A/es unknown
- 2023-06-16 EC ECSENADI202345278A patent/ECSP23045278A/es unknown
-
2024
- 2024-03-27 US US18/619,017 patent/US20240391914A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CR20230262A (es) | 2023-07-26 |
| PE20240114A1 (es) | 2024-01-22 |
| CU20230026A7 (es) | 2024-01-10 |
| ECSP23045278A (es) | 2023-07-31 |
| EP4247472A1 (en) | 2023-09-27 |
| US12018025B2 (en) | 2024-06-25 |
| US20220177468A1 (en) | 2022-06-09 |
| US20240391914A1 (en) | 2024-11-28 |
| AU2021381516A9 (en) | 2024-10-24 |
| CO2023006522A2 (es) | 2023-06-09 |
| CN116710169A (zh) | 2023-09-05 |
| AU2021381516A1 (en) | 2023-06-22 |
| JP2023550428A (ja) | 2023-12-01 |
| EP4247472A4 (en) | 2024-10-09 |
| CL2023001418A1 (es) | 2023-10-30 |
| IL302651A (en) | 2023-07-01 |
| DOP2023000101A (es) | 2023-09-29 |
| TW202235417A (zh) | 2022-09-16 |
| MX2023005889A (es) | 2023-06-06 |
| KR20230121761A (ko) | 2023-08-21 |
| WO2022109598A1 (en) | 2022-05-27 |
| CA3173755A1 (en) | 2022-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023005889A (es) | Inhibidor de integrina y usos de este. | |
| JOP20220351A1 (ar) | صيغ من 19-nor c3، وسترويد 3- بيرازول-c21-n- بيرازول ليس به استبدال وطرق استخدامه | |
| CY1124206T1 (el) | Αναστολεις πυριδοπυριμδινονης cdk2/4/6 | |
| MX2020011294A (es) | Derivados de 2-amino-piridina o 2-amino-pirimidina como inhibidores de cinasa dependientes de ciclina. | |
| MX2021009276A (es) | Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibidora sobre cdk2. | |
| CR20200452A (es) | Compuestos de aminoacidos y métodos de uso | |
| EA201000268A1 (ru) | Производные n-(ариламино)сульфонамидов, включая полиморфы, в качестве ингибиторов mek, а также композиции, способы применения и способы их приготовления | |
| PH12020552187A1 (en) | Pcsk9 antagonist compounds | |
| MY158648A (en) | Compositions for modulating a kinase cascade and methods of use thereof | |
| CU20210001A7 (es) | Compuestos de aminoácido con ligadores no ramificados como inhibidores de la integrina y composiciones farmacéuticas que los comprenden | |
| EA201991399A1 (ru) | Аминотриазолопиридиновые соединения и их применение в лечении рака | |
| UA108369C2 (uk) | Піролопіримідини як інгібітори cdk4/6 | |
| CY1118146T1 (el) | Σταθερες σε αποθηκευση φαρμακοτεχνικες μορφες σουλφοναμιδιων | |
| SI2185155T1 (en) | Pharmaceutical compositions containing dopamine receptor ligands and treatment procedures using ligands of dopamine receptors | |
| FI20115234A0 (fi) | Uusia pyridatsinoni- ja pyridoniyhdisteitä | |
| CY1120647T1 (el) | Κρυσταλλοι ενωσης 2-ακυλαμινοθειαζολη | |
| MX2016001096A (es) | Sales de dasatinib en forma amorfa. | |
| MY206797A (en) | Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain | |
| JOP20210072A1 (ar) | ملح جديد لمثبط bcl-2، صورة بلورية ذات صلة، طريقة تحضيره وتركيبات صيدلية تحتوي عليه | |
| GEP20125433B (en) | α CRYSTALLINE FORM OF THE ARGININE SALT OF PERINDOPRIL, PROCESS FOR PREPARING IT, AND PHARMACEUTICAL COMPOSITIONS COMPRISING IT | |
| MX2024005429A (es) | Inhibidores de las fosfatidilinositol 3-cinasas-alfa (pi3k-alfa) y metodos para su produccion y uso. | |
| PL441331A1 (pl) | Ulepszenia inhibitorów nitryfikacji i ulepszenia dotyczące inhibitorów nitryfikacji | |
| JOP20240171A1 (ar) | مركبات يوراسيل بها استبدال بـ n3 على هيئة مثبطات trpa1 | |
| BR112016005509A8 (pt) | método de preparação de um extrato de sementes de urucum (anato), composição, extrato vegetal, e composição farmacêutica | |
| MX2025012347A (es) | Compuestos heterociclicos y usos de estos |